由于过继转移的自然杀伤(NK)细胞寿命较短,副作用较少,并且对AML具有内在的CAR非依赖性杀伤能力,因此CD33-CAR-NK细胞就成了一种有前景的替代品。 2022年4月,Blood cancer journal期刊上发表了题为“Primary CD33-targeting CAR-NK cells ...
5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μLof 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-LabeledHuman Siglec-3, His Tag (Cat. No.CD3-HP2E3)and negative control protein respectively. PE signal was used to evaluate the binding activity. 点击...
6. Shamsasenjan K, Otsuyama KI, Abroun S, et al. IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells. Int J Hematol. 2009,89(3) :310-318. 7. 许超平, 周涛, 胡桂英,等. vdac-1...
Rigolin, Gian MatteoLanza, FrancescoFerrari, LuisaCastoldi, GianluigiTaylor & FrancisLeukemia and LymphomaRigolin GM,et al.CD34+/CD33+ blast cells:correlation with FAB subtypes. Leukemia and Lymphoma . 1995Rigolin GM,et al.CD34+/CD33+ blast cells:correlation with FAB subtypes. Leukemia and ...
CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 Domain (s) that ...
The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998; 22: 469-475.Millar B C,Millar J L,Shepherd V,et al.The importance of CD34+ /CD33- cells in platelet engraftment after...
2020年11月16日/医麦客新闻 eMedClub News/--Vor Biopharma总部位于美国马萨诸塞州,由PureTech与哥伦比亚肿瘤学家、普利策奖获奖作家Siddhartha Mukherjee于2016年创立,是开发工程化造血干细胞(eHSC)用于癌症治疗的领军企业。近日(2020年11月12日),Vor Biopharma宣布,与美国国立卫生研究院(NIH)下属国家癌症研究所(NCI...
中文摘要 急性白血病CDl33和CD34的表达及意义 摘 要 的表达及其与白血病类型、不同病期及预后之间的关系,进一步阐明其 意义。 方法:应用流式细胞术检测52例急性白血病和20例巨幼细胞性贫 18.0统计软件进行分析。 结果: (PO.01)。 2 31.3%和54.3%VS50.O%,无显著差异(PO.05)。 VS 37.5%,差异无显著性(PO...
Human hematopoietic stem cells are thought to express the CD34 stem cell antigen, low numbers of HLA-DR and Thy1 antigens, but no lineage commitment antigens, CD38, or CD45RA antigens. However, fluorescence-activated cell sorted CD34+ subpopulations contain not more than 1% to 5% primitive ...
1. Zhenzhen Wang, et al. CD123-CD33 COMPOUND CAR-T CELLS WITH NOVEL ANTIGEN BINDING DOMAINS PROVIDE A NEW HOPE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. 2022 EHA. Abstract S121. 编辑:Wenting 审校:Quinta 排版:Wenting...